Treatment of Nonmetastatic Castration Resistant Prostate Cancer

被引：1
|
作者：
Luo, Jia [1 ]
Beer, Tomasz M. [2 ]
Graff, Julie N. [2 ,3 ]
机构：
[1] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[3] VA Portland Hlth Care Syst, Portland, OR USA
来源：
ONCOLOGY-NEW YORK | 2016年 / 30卷 / 04期
关键词：
METASTASIS-FREE SURVIVAL; ANDROGEN-RECEPTOR GENE; ANTIANDROGEN WITHDRAWAL; PHASE-III; MEN; THERAPY; HORMONE; ENZALUTAMIDE; BICALUTAMIDE; COMBINATION;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with nonmetastatic castration-resistant prostate cancer (CRPC) are a heterogeneous population with regard to risk of progression to metastatic disease. Treatment selection for nonmetastatic CRPC must balance the risk of disease progression with the side effects of available therapies. Several medication classes are available for use in treating these patients, and other newer agents are under active clinical trial investigation. Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.
引用
收藏
页码：336 / 344
页数：9
相关论文
共 50 条
  • [41] An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer
    Brave, Michael
    Weinstock, Chana
    Brewer, Jamie R.
    Chi, Dow-Chung
    Suzman, Daniel L.
    Cheng, Joyce
    Zhang, Lijun
    Sridhara, Rajeshwari
    Ibrahim, Amna
    Kluetz, Paul G.
    Pazdur, Richard
    Beaver, Julia A.
    CLINICAL CANCER RESEARCH, 2020, 26 (18) : 4717 - 4722
  • [42] Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
    George, Daniel J.
    Morgans, Alicia K.
    Constantinovici, Niculae
    Khan, Nasreen
    Khan, Javeed
    Chen, Guifang
    Hlebec, Vlasta
    Shore, Neal D.
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [43] ARAMIS: Efficacy and Safety of Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 2 - 5
  • [44] Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
    Saad, Fred
    Boegemann, Martin
    Suzuki, Kazuhiro
    Shore, Neal
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (02) : 323 - 334
  • [45] Real-world treatment patterns among veterans with nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Halwani, Ahmad Sami
    Patil, Vikas
    Morreall, Deborah
    Li, Chunyang
    Yong, Christina
    Appukkutan, Sreevalsa
    Partridge, Jamie
    Jhaveri, Jay
    Rasmussen, Kelli Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17042 - E17042
  • [46] Understanding Treatment Strategies and Preferences in Nonmetastatic Castration-Resistant Prostate Cancer From the Japanese Physician Perspective
    Suzuki, Kazuhiro
    Grillo, Vince
    Chen, Yirong
    Singh, Shikha
    Ledesma, Dianne Athene
    JCO GLOBAL ONCOLOGY, 2021, 7 : 302 - 310
  • [47] Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
    Fred Saad
    Martin Bögemann
    Kazuhiro Suzuki
    Neal Shore
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 323 - 334
  • [48] Impact of Darolutamide on Local Symptoms in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 11 - 12
  • [49] ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Fizazi, Karim
    Shore, Neal D.
    Tammela, Teuvo
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris Y.
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [50] PSMA PET-CT redefines nonmetastatic castration-resistant prostate cancer
    Ost, Piet
    NATURE REVIEWS UROLOGY, 2020, 17 (03) : 133 - 134
12345